Author | Tony Hagen | OncLive

Author | Tony Hagen


ASCO Identifies Additional Ways to Improve Hazardous Drug Safety

February 24, 2020

The United States Pharmacopeial Convention (USP) General Chapter is a good start for improving the protection of healthcare workers exposed to hazardous drugs, but more studies and safety protocols are needed, according to an American Society of Clinical Oncology (ASCO) expert panel that evaluated USP and various other guidelines in a report last year.

Practices Make Surprise Decision on OCM Risk

January 30, 2020

Many practices enrolled in the Oncology Care Model were expected to drop out of the value-based model rather than take on 2-sided risk, which would entail upside and downside financial exposure.

T-Cell Immunotherapy Pioneer Seeks New Direction for Solid Tumors

January 11, 2020

CAR T cells are a highly active field of investigation, with many companies at work on formulations they hope to bring to market, but these agents have limitations, particularly with metastasized solid tumors.

Pazdur Followed the Pathway of Greatest Resistance to the FDA

December 30, 2019

Richard Pazdur, MD, set out to be a leader in medicine and a teacher of doctors. He achieved that and more, turning the oncology drugs section of the FDA from a poorly understood and lead-footed division into a fast-moving and patient-responsive entity.